Standard BioTools Inc. — Earnings Quality Grade C
LAB · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 57 days, change -2 days YoY
AR growth -8.9% vs revenue growth -6.2%
Revenue -6.2%, CFFO 48.2%. Cash follows revenue
Expense Quality
Inventory -3.7% vs COGS -7.2%. Normal
CapEx growth -0.6% vs revenue -6.2%. Normal
SG&A/Gross Profit = 258.2%, exceeds 70%
Gross margin 49.9%, change +0.5pp. Stable
Cash Flow Quality
CFFO/NI = 0.99. Profits backed by cash
FCF is negative ($-0.1B)
Accruals ratio = -0.1%. Low accruals
Cash $0.2B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -3588.7x (<2x). Financial stress
Other assets -98.3% vs revenue -6.2%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
Goodwill+Intangibles change -100% YoY. Normal
Manipulation Score
M-Score = -3.06 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor LAB continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25